Although this marker is more commonly discussed in the context of Hodgkin lymphoma, one study involving 903 patients with DLBCL treated with R-CHOP found that CD30 positivity was associated with improved progression-free survival and overall survival at five years [6]. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.